Fecal microbiota transplantation in patients with metabolic syndrome and obesity : A randomized controlled trial
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.
AIM: To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.
METHODS: This was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.
RESULTS: There was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.
CONCLUSION: There were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
World journal of clinical cases - 11(2023), 19 vom: 06. Juli, Seite 4612-4624 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
da Ponte Neto, Alberto Machado [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetes mellitus |
|---|
| Anmerkungen: |
Date Revised 21.07.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12998/wjcc.v11.i19.4612 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359701795 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359701795 | ||
| 003 | DE-627 | ||
| 005 | 20231226081433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12998/wjcc.v11.i19.4612 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359701795 | ||
| 035 | |a (NLM)37469721 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a da Ponte Neto, Alberto Machado |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fecal microbiota transplantation in patients with metabolic syndrome and obesity |b A randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease | ||
| 520 | |a AIM: To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome | ||
| 520 | |a METHODS: This was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota | ||
| 520 | |a RESULTS: There was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated | ||
| 520 | |a CONCLUSION: There were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Endocrinology | |
| 650 | 4 | |a Endoscopy | |
| 650 | 4 | |a Fecal microbiota transplantation | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Obesity | |
| 700 | 1 | |a Clemente, Aniele Cristine Ott |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Paula Waki |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Igor Braga |e verfasserin |4 aut | |
| 700 | 1 | |a Funari, Mateus Pereira |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Gabriel Cairo |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Luana |e verfasserin |4 aut | |
| 700 | 1 | |a Sparvoli, Luiz Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Cortez, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Taddei, Carla Romano |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, Márcio C |e verfasserin |4 aut | |
| 700 | 1 | |a de Moura, Eduardo Guimarães Hourneaux |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of clinical cases |d 2013 |g 11(2023), 19 vom: 06. Juli, Seite 4612-4624 |w (DE-627)NLM233331727 |x 2307-8960 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:19 |g day:06 |g month:07 |g pages:4612-4624 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12998/wjcc.v11.i19.4612 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 19 |b 06 |c 07 |h 4612-4624 | ||